90 related articles for article (PubMed ID: 15574789)
1. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.
Berger AJ; Camp RL; Divito KA; Kluger HM; Halaban R; Rimm DL
Cancer Res; 2004 Dec; 64(23):8767-72. PubMed ID: 15574789
[TBL] [Abstract][Full Text] [Related]
2. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
Polsky D; Bastian BC; Hazan C; Melzer K; Pack J; Houghton A; Busam K; Cordon-Cardo C; Osman I
Cancer Res; 2001 Oct; 61(20):7642-6. PubMed ID: 11606406
[TBL] [Abstract][Full Text] [Related]
3. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
Divito KA; Berger AJ; Camp RL; Dolled-Filhart M; Rimm DL; Kluger HM
Cancer Res; 2004 Dec; 64(23):8773-7. PubMed ID: 15574790
[TBL] [Abstract][Full Text] [Related]
4. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
5. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
6. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome.
Kielhorn E; Provost E; Olsen D; D'Aquila TG; Smith BL; Camp RL; Rimm DL
Int J Cancer; 2003 Feb; 103(5):652-6. PubMed ID: 12494474
[TBL] [Abstract][Full Text] [Related]
8. Nuclear ING2 expression is reduced in human cutaneous melanomas.
Lu F; Dai DL; Martinka M; Ho V; Li G
Br J Cancer; 2006 Jul; 95(1):80-6. PubMed ID: 16755297
[TBL] [Abstract][Full Text] [Related]
9. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
12. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray.
Pacifico MD; Grover R; Richman PI; Daley FM; Buffa F; Wilson GD
Int J Cancer; 2006 Mar; 118(6):1460-4. PubMed ID: 16187282
[TBL] [Abstract][Full Text] [Related]
13. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
14. HDM2 protein overexpression and prognosis in primary malignant melanoma.
Polsky D; Melzer K; Hazan C; Panageas KS; Busam K; Drobnjak M; Kamino H; Spira JG; Kopf AW; Houghton A; Cordon-Cardo C; Osman I
J Natl Cancer Inst; 2002 Dec; 94(23):1803-6. PubMed ID: 12464652
[TBL] [Abstract][Full Text] [Related]
15. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
16. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
Bachmann IM; Puntervoll HE; Otte AP; Akslen LA
Mod Pathol; 2008 May; 21(5):583-90. PubMed ID: 18246051
[TBL] [Abstract][Full Text] [Related]
17. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
18. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
[TBL] [Abstract][Full Text] [Related]
19. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
20. Expression of apoptosis regulators in cutaneous malignant melanoma.
Tang L; Tron VA; Reed JC; Mah KJ; Krajewska M; Li G; Zhou X; Ho VC; Trotter MJ
Clin Cancer Res; 1998 Aug; 4(8):1865-71. PubMed ID: 9717813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
